Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study of Weekly Topotecan in Combination With Bevacizumab (Avastin) in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy.

Next Previous
Trial Profile

Phase II Clinical Study of Weekly Topotecan in Combination With Bevacizumab (Avastin) in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Topotecan (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 22 Feb 2011 Planned end date changed from Dec 2009 to May 2011 as reported by ClinicalTrials.gov.
  • 27 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top